美东时间7月23日,美股生物技术公司Abivax股价盘初一度暴涨超596%,最终收涨586%,最新市值43.48亿美元。消息面上,Abivax宣布,其首创新型口服miR-124增强剂Obefazimod在中度至重度溃疡性结肠炎的ABTECT 8周诱导试验中取得积极的III期结果。公司还称,准备在2026年下半年向FDA提交新药申请。美股创新药黑马有分析称,Abivax有望成为美股创新药板块的“黑马...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.